Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-058 and Ondansetron on P50 Auditory Gating in Schizophrenia
NCT02614586Phase 1Terminated
- Sponsor
- Takeda
- Start
- Dec 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-058 in schizophrenia (6 arms), sponsored by Takeda. Primary endpoint: Change From Baseline in P50 Ratio S2/S1 at Central (Cz) Electrode. Started Dec 2015; status: terminated.
02
Drugs
TAK-058
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02614586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614586.